ALKERMES | ALKS - Cost Of Sales


ALKERMES reported $51.59M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Acadia Pharmaceuticals USD 21.65M 913K Sep/2025
ALKERMES USD 51.59M 2.13M Sep/2025
Amgen USD 1.79B 128M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 144.93M 10M Sep/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Gilead Sciences USD 1.57B 68M Sep/2025
Ionis Pharmaceuticals USD 2.34M 1.81M Sep/2025
J&J USD 7.97B 689M Dec/2025
Merck USD 3.32B 531M Dec/2025
Neurocrine Biosciences USD 264M 252.7M Sep/2025
Otsuka Holdings JPY 180.95B 12.18B Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Vertex Pharmaceuticals USD 414.8M 7.3M Sep/2025